From the Guidelines
Femenista Plus is contraindicated in women with a history of breast cancer, liver disease, myocardial infarction, known or suspected estrogen-dependent neoplasia, deep vein thrombosis, or thrombophilic disorders. These conditions increase the risk of adverse effects from the hormonal components of Femenista Plus. According to the 2024 guideline for the primary prevention of stroke by the American Heart Association/American Stroke Association 1, assessing for contraindications to menopausal hormone therapy use is crucial. The guideline lists specific contraindications, including history of breast cancer, liver disease, history of myocardial infarction, known or suspected estrogen-dependent neoplasia, history of deep vein thrombosis, and thrombophilic disorders.
Some key points to consider when evaluating the use of Femenista Plus include:
- History of breast cancer or other estrogen-dependent neoplasms
- Active or recent arterial thromboembolic disease, such as stroke or myocardial infarction
- Active venous thromboembolism or a history of these conditions
- Severe liver disease
- Undiagnosed abnormal vaginal bleeding
- Known or suspected pregnancy
- Hypersensitivity to any components of the product
It is essential to consult with a healthcare provider before starting Femenista Plus to ensure it is appropriate for the individual's specific health situation, considering the potential risks and benefits. The healthcare provider should assess for contraindications and discuss alternative treatment options if necessary.
The evidence from the 2024 guideline 1 provides the most recent and highest quality information on the contraindications for menopausal hormone therapy, including Femenista Plus. While other studies, such as those from 2017 1, 2013 1, 2012 1, and 2012 1, provide additional information on the risks and benefits of hormone therapy, the 2024 guideline offers the most up-to-date and relevant guidance on contraindications.
From the Research
Femenista Plus Contraindication
- There are no research papers to assist in answering this question regarding "femenista plus contraindication" as the provided studies focus on thromboembolism in pregnancy, its diagnosis, treatment, and prevention.
- However, the studies do mention contraindications for certain medications during pregnancy, such as:
- These studies provide information on the management of thromboembolism in pregnancy, including the use of low-molecular-weight heparin for prophylaxis and treatment 2, 3.